Xencor reports Q1 net loss $128.9M ($1.71/shr); revenue down to $4.5M from $32.7M

Xencor Inc

2026-Q1 EPS reported -$1.71 revenue$4,516,000

Q1 2026 revenue $4.5M (vs $32.7M Q1 2025), including a $6.6M one-time reduction from Alexion royalty dispute.
Net loss $128.9M ($1.71 diluted), vs $48.4M ($0.66) in prior year; other expense $50.8M on unrealized equity losses.
Cash $541.8M at March end; guidance for year-end cash $380-400M, runway into mid-2028.
XmAb819 ccRCC expansion data to be presented 2H26; XmAb541 dose data also 2H26; XmAb412 FIH starts 3Q26.
XENITH-UC Phase 2b (XmAb942) blinded interim analysis around year-end 2026; primary endpoint 2H27.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xencor Inc reported the first quarter ended March 31, 2026 results: revenue $4.5 million. Guidance reaffirmed.

Period: the first quarter ended March 31, 2026
Revenue: $4.5 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

debt securities totaled $541.8 million as of March 31, 2026, compared to $610.8 million as of December 31, 2025. Revenue for the first quarter ended March 31, 2026 was $4.5 million, compared to $32.7 million for the same period in 2025. Revenue earned in the first quarter of 2026 was primarily non-cash royalty revenue from Incyte and Alexion, compared to

View on SEC.gov

Browse all earnings releases →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-26-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.